Green Cross Corp., of Yongin, South Korea, said the FDA accepted for review the biologics license application for IVIG-SN (human normal immunoglobulin G for intravenous administration) intended for the treatment of primary immunodeficiency diseases (PID), a class of inherited genetic disorders that causes an individual to have a deficient or absent immune system. Read More

Cellular Biomedicine Group, of Shanghai,appointed Terry A. Belmont chairman of the board, and Tony (Bizuo) Liu CEO, effective Feb. 7. Belmont has been an independent director since December 2013 and vice chairman of the board since March 2015. He retired in June 2015 as CEO at University of California, Irvine Health. Read More

HONG KONG – Shanghai-based Carsgen Therapeutics Ltd. closed a $30 million series B financing and now aims to push more of its products to clinical trials at home and abroad. Carsgen plans to complete phase I studies of the two therapeutics, CSG-EGFR and CSG-GPC3 by the end of 2016. The drugs are being developed to treat brain, lung and liver cancers. The primary market is China. Read More

Chinese researchers have reported the creation of two generations of transgenic macaque monkeys bearing a gene duplication of the MeCP2 gene. In humans, MeCP2 duplication syndrome is a childhood neurological disorder that is part of the autism spectrum, and the monkeys showed some of the behavioral symptoms that are typical of MeCP2 duplication syndrome, though they lacked the cognitive symptoms that are a prominent feature of the disorder in humans. Read More

HONG KONG – 3SBio Inc. continues along its expansionary path with a move to raise the stake it holds in Shanghai CP Guojian Pharmaceutical Co. Ltd. The latest acquisition is another step in a push toward full integration of the two companies. Read More

HONG KONG – With the successful completion of a phase II study in the U.S. for its flagship product, VM202, for the treatment of critical limb ischemia (CLI), South Korean biopharma Viromed Co. Ltd. is off to a good start this year. Read More

SHANGHAI – Suzhou, China-based Adagene Inc. received $28 million in series B financing to further enhance its technology-driven antibody discovery platform and nudge its own portfolio of innovative antibodies, against targets related to cancer and other diseases, closer to the clinic. Read More

HONG KONG – A promising cancer orphan drug could soon be available in a string of major and emerging Asian markets, marking the next step in a multinational partnership for global commercialization and research. Read More

HONG KONG – The Korean Ministry of Food and Drug Safety (MFDS) is shortening the biologics review process for rare and incurable diseases to speed up the approvals and overseas distribution of Korea-developed biopharmaceuticals. Although details of the policy are sketchy and yet to be disclosed, the announcement marks the country's determination to make biopharmaceuticals a core industry. Read More